{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:37:01Z","timestamp":1792816621814,"version":"4.5.0"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.rmed.2026.109216","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:11:29Z","timestamp":1791990689000},"page":"109216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tofacitinib in rheumatoid arthritis-associated interstitial lung disease: immunomodulation and antifibrotic therapy as complementary strategies?"],"prefix":"10.1016","author":[{"given":"Freddy","family":"Li\u00f1\u00e1n-Ponce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2026.109216_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2026.109150","article-title":"Tofacitinib reduces KL-6 levels in patients with rheumatoid arthritis-associated interstitial lung disease. Results of a phase II investigator-initiated study","volume":"263","author":"Rojas-Serrano","year":"2026","journal-title":"Respir. Med."},{"issue":"11","key":"10.1016\/j.rmed.2026.109216_bib2","first-page":"2071","article-title":"Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: treasure real-life data","volume":"40","author":"Kalyoncu","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.rmed.2026.109216_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005062","article-title":"Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study","volume":"11","author":"Triboulet","year":"2025","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.rmed.2026.109216_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103636","article-title":"Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"23","author":"Narv\u00e1ez","year":"2024","journal-title":"Autoimmun. Rev."},{"issue":"9","key":"10.1016\/j.rmed.2026.109216_bib5","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-023-06623-7","article-title":"Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial","volume":"42","author":"Matteson","year":"2023","journal-title":"Clin. Rheumatol."},{"issue":"8","key":"10.1016\/j.rmed.2026.109216_bib6","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/acr.25348","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126005858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126005858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:47:30Z","timestamp":1792813650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126005858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":6,"alternative-id":["S0954611126005858"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.109216","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tofacitinib in rheumatoid arthritis-associated interstitial lung disease: immunomodulation and antifibrotic therapy as complementary strategies?","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.109216","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109216"}}